Ravulizumab for severe pregnancy hypertension disorders
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study tests a medicine called Ravulizumab for pregnant people with severe high blood pressure problems (preeclampsia or HELLP syndrome) before 34 weeks of pregnancy. The goal is to see if the drug can help manage the condition and improve outcomes for both mother and baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are less than 34 weeks pregnant.
- You have severe preeclampsia or HELLP syndrome (a serious pregnancy complication).
- You do not have severe blood clotting problems (like DIC), a stroke, rare kidney/blood disorders (aHUS, TTP, PNH), or an allergy to the study drug.
- Your baby is not in immediate danger requiring delivery, and the pregnancy is beyond 23 weeks.
- You are able and willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using specific blood-pressure medicines can help people with non-severe preeclampsia stay pregnant longer. It aims to improve outcomes by treating blood pressure early while monitoring you and the baby closely.
This study is testing a new treatment strategy for women with preeclampsia, a serious pregnancy condition that causes high blood pressure. If you have preeclampsia or a normal pregnancy, you may be able to join to help find better treatments.
This trial tests whether adding aspirin and hydroxychloroquine can lower the risk of preeclampsia during pregnancy in people considered high-risk. If you qualify, you may be assigned to take the study medicines to help protect you and the baby.
This trial tests a new medicine, CBP-4888, for pregnant women hospitalized with preeclampsia starting after 20 weeks. The goal is to see if it's safe and how it works for you and your baby, who will be followed for up to 24 months after birth.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Hear when a new Preeclampsia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.